Rafael Holdings, Inc.

Rafael Holdings, Inc. ( Rafael Holdings , Rafael , we or the Company ) is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol Cyclo , which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 ( NPC1 ), a rare, fatal and progressive genetic disorder. We also hold: (i) a majority equity interest in LipoMedix Pharmaceuticals Ltd. ( LipoMedix ), a clinical stage pharmaceutical company; (ii) Barer Institute Inc. ( Barer ), a wholly-owned cancer research focused entity whose operations have been substantially curtailed; (iii) a majority interest in Cornerstone Pharmaceuticals, Inc. ( Cornerstone ), formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company; (iv) a majority interest in Rafael Medical Devices, LLC ( Rafael Medical Devices ), an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries; and (v) a majority interest in Day Three Labs, Inc. ( Day Three ), a company which empowers third-party manufacturers to reimagine their existing product offerings by utilizing Day Three’s technology and innovation like Unlokt . Our primary focus has been the continued development of Trappsol Cyclo through the completion of its ongoing pivotal Phase 3 clinical trial, the potential filing for regulatory approval and ultimately, if approved, commercialization of the product.